HoneyBear Biosciences, Inc is a Taiwan-based biotech company that is leveraging its proprietary antibody-drug conjugation platform – CoNectar™ – for global drug development.
Founded in 2021, HoneyBear Biosciences, Inc is a Taiwan-based biotech company targeting the global pharmaceutical market. We strive to develop new antibody technologies to deliver novel therapeutics to the cancer patients.
Our business strategy consists of utilizing our powerful antibody engineering platforms to develop and commercialize novel Antibody-Drug Conjugates (ADC) through licensing and co-development partnership with biotech and pharmaceutical companies.
Our vision
To improve the therapeutic outcomes for cancer patients through innovative pharmaceutical solutions.
Our mission
To leverage our chemical and biochemical innovations to create the next wave of effective anti-cancer medicines.
Our values
Innovation, integrity, responsibility
Experienced international management team
We have a highly qualified management team with diverse and international experience in both chemistry and the biological sciences, stemming from innovative research in academic and biotechnology settings, coupled with rigorous development experience in global pharmaceutical companies.
Our leadership team
Edward Wang
Chairman & President
Former Vice Chairman, Petrochemical Industry Association of Taiwan
Former President, USI Corporation and CPDC
Simon Shih-Hsien Chuang, Ph.D.
CEO
Inventor of CoNectar™ platform technology
Co-founder of HoneyBear Biosciences
Sarina Lin, M. Sc.
VP, Business Development
Executive Director at Novartis (1996-2020)
Expertise in commercial excellence
Carol Huang, Ph.D.
VP, Manufacturing
Executive Director at Amgen and VP at Five Prime Therapeutics
Expertise in antibody manufacture and CMC strategics
Michael Evans, Ph.D.
Scientific co-founder
UCSF Professor, Department of Radiology & Biomedical Imaging
Expertise in Radiotherapy & Imaging
David S. Wilson, Ph.D.
Head of Biologics Development
Biotechnology Consultant
Former VP of Discovery Research, Teva Pharmaceuticals
Weichyun Wong
CMC consultant and major investor
Chairman and CEO of SCI PHARMTECH
Expertise in API manufacture and CMC
